Navigation Links
Casing the joint

St. Louis, MO Current research provides a novel model for rheumatoid arthritis research. The related report by LaBranche et al, "Characterization of the KRN cell transfer model of rheumatoid arthritis (KRN-CTM), a chronic yet synchronized version of the K/BxN mouse," appears in the September 2010 issue of The American Journal of Pathology.

Nearly 1% of the population is affected by rheumatoid arthritis, and women are affected three to five times more often then men. Although the course of disease varies greatly, daily living activities are impaired in most affected individuals and after 5 years approximately 33% of sufferers are no longer able to work.

Rheumatoid arthritis is characterized by chronic inflammation of the distal joints and is mediated in part by emigration and activation of immune cells. The restrictions of present animal models, which either mimic chronic disease or a synchronized version of early disease (but not both), have hampered scientific understanding of the specific roles immune cells and their mediators play in disease initiation and maintenance. In this regard, Dr. Paul Allen and colleagues at the Washington University in St. Louis School of Medicine, in collaboration with Dr. Timothy LaBranche and colleagues at Pfizer Global Research & Development developed and characterized a chronic yet synchronized animal model of rheumatoid arthritis (KRN-CTM). Disease in these animals developed with a uniform onset of 7 days post-initiation and was maintained chronically (through Day 42). These mice revealed a time course of rheumatoid arthritis characteristics including edema, immune cell infiltration, cartilage damage and osteoclast-mediated bone resorption.

According to Dr. LaBranche, "the main benefit of the KRN-CTM is its utility, which adds significant logistical and platform advantages to study T cell targets since the model is T cell-dependent and engages both early and late stages of innate and adaptive immune responses (a drawback of the antibody-dependent K/BxN serum transfer model). In addition, by polarizing T helper (Th) cells and/or knocking down genes prior to transfer, the KRN-CTM may enable investigators to ask how specific Th subsets and/or specific T cell genes contribute to disease. Lastly, incidence, onset, and severity of disease are highly synchronized without requiring adjuvant. The KRN-CTM presents a novel opportunity for investigators to study specific pathways and mechanisms involved in both the early and chronic phases of disease, thereby enabling the validation of targets and biopharmaceuticals for rheumatoid arthritis patients."

In future studies Dr.'s Allen and LaBranche aim to demonstrate the utility of the KRN-CTM, illustrating the roles Th subsets and particular genes have in both the model and people.


Contact: Angela Colmone, Ph.D.
American Journal of Pathology

Related biology news :

1. BIO-key(R) International Showcasing Biometric Identification Technology at 2009 RSA Conference
2. Most panda habitat is outside nature reserves according to joint MSU-Chinese research
3. NTU and UNSW open joint center to study microorganisms for water and environment technologies
4. U-M joins with Chinese university to jointly fund renewable energy and biomedical research projects
5. DOE Joint Genome Institute 5th Annual Meeting on March 24-26, 2010
6. TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services
7. Joint US-Norwegian study provides new insights into marine ecosystems and fisheries production
8. Laser processes promise better artificial joints, arterial stents
9. Joint research into an enzyme that causes genetic diseases
10. Joint statement by German science organizations on green genetic engineering
11. Imperial College London and NTU collaborate to offer joint Ph.D. programs in engineering and science
Post Your Comments:
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/27/2015)... 27, 2015 Munich, Germany ... Mapping technology (ASGM) automatically maps data from mobile eye ... , so that they can be quantitatively analyzed ... Munich, Germany , October 28-29, 2015. SMI,s ... from mobile eye tracking videos created with SMI,s ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... TapImmune, Inc. (TPIV), a ... peptide and gene-based immunotherapeutics and vaccines for the treatment ... be presenting at the 8 th Annual LD ... PM PT. Dr. John N. Bonfiglio a ... the presentation and will join TapImmune management in meeting ...
(Date:11/30/2015)...  Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage specialty ... present at two upcoming investor conferences. Aytu is scheduled ... conference, to be held December 3, 2015, and at ... December 2 nd & 3 rd , 2015 ... live via webcast. Josh Disbrow , Chief ...
(Date:11/30/2015)... RATON, Florida and MAGDEBURG, Germany ... Congress of NeuroRehabilitation (ECNR) in Vienna, Austria ... 3rd European Congress of NeuroRehabilitation (ECNR) in ... 2015. --> NovaVision, a wholly owned subsidiary of ... the European version of its Internet-delivered NovaVision Therapy Suite at ...
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... Company, today announced tighter software integration with MarkLogic, the Enterprise NoSQL database ... maximize information to drive change. , Smartlogic’s Content Intelligence capabilities provide a ...
Breaking Biology Technology: